- Home
- RYAN vs TFX Comparison
RYAN vs TFX Comparison
Compare RYAN & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYAN
- TFX
- Stock Information
- Founded
- RYAN 2010
- TFX 1943
- Country
- RYAN United States
- TFX United States
- Employees
- RYAN N/A
- TFX N/A
- Industry
- RYAN Specialty Insurers
- TFX Medical/Dental Instruments
- Sector
- RYAN Finance
- TFX Health Care
- Exchange
- RYAN Nasdaq
- TFX Nasdaq
- Market Cap
- RYAN 8.5B
- TFX 8.4B
- IPO Year
- RYAN 2021
- TFX N/A
- Fundamental
- Price
- RYAN $64.95
- TFX $177.11
- Analyst Decision
- RYAN Buy
- TFX Buy
- Analyst Count
- RYAN 12
- TFX 8
- Target Price
- RYAN $73.50
- TFX $259.00
- AVG Volume (30 Days)
- RYAN 798.8K
- TFX 438.7K
- Earning Date
- RYAN 10-30-2024
- TFX 10-31-2024
- Dividend Yield
- RYAN 0.67%
- TFX 0.76%
- EPS Growth
- RYAN 53.91
- TFX N/A
- EPS
- RYAN 0.77
- TFX 5.03
- Revenue
- RYAN $2,324,982,000.00
- TFX $3,025,824,000.00
- Revenue This Year
- RYAN $26.22
- TFX $4.52
- Revenue Next Year
- RYAN $20.37
- TFX $4.86
- P/E Ratio
- RYAN $84.52
- TFX $35.65
- Revenue Growth
- RYAN 20.14
- TFX 2.27
- 52 Week Low
- RYAN $41.57
- TFX $176.65
- 52 Week High
- RYAN $75.97
- TFX $256.85
- Technical
- Relative Strength Index (RSI)
- RYAN 27.84
- TFX 27.79
- Support Level
- RYAN $66.83
- TFX $176.65
- Resistance Level
- RYAN $67.85
- TFX $188.87
- Average True Range (ATR)
- RYAN 1.48
- TFX 4.40
- MACD
- RYAN -0.96
- TFX 0.17
- Stochastic Oscillator
- RYAN 1.67
- TFX 6.89
About RYAN Ryan Specialty Holdings Inc.
Ryan Specialty Holdings Inc is a service provider of specialty products and solutions for insurance brokers, agents, and carriers. It provides distribution, underwriting, product development, administration, and risk management services by acting as a wholesale broker and a managing underwriter.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2023 sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and other (10%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.